Float Short %

7.21

Margin Of Safety %

Put/Call OI Ratio

0.55

EPS Next Q Diff

0.22

EPS Last/This Y

0.5

EPS This/Next Y

0.36

Price

7.61

Target Price

16.09

Analyst Recom

1.33

Performance Q

21.57

Relative Volume

0.84

Beta

0.52

Ticker: FOLD

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-28	FOLD	6.12	0.59	0.07	13424
2025-07-29	FOLD	6.14	0.59	0.00	13472
2025-07-30	FOLD	6.12	0.59	0.01	13475
2025-07-31	FOLD	5.99	0.56	0.24	13422
2025-08-01	FOLD	6.32	0.55	0.16	13579
2025-08-04	FOLD	6.84	0.55	0.06	13617
2025-08-05	FOLD	6.99	0.52	0.00	14252
2025-08-06	FOLD	6.93	0.52	0.93	14257
2025-08-07	FOLD	6.8	0.54	0.00	14406
2025-08-08	FOLD	6.77	0.53	0.00	14622
2025-08-11	FOLD	6.66	0.53	0.25	14654
2025-08-12	FOLD	6.97	0.53	0.00	14657
2025-08-13	FOLD	7.2	0.53	0.76	14668
2025-08-14	FOLD	7.11	0.57	0.11	16717
2025-08-15	FOLD	7.41	0.58	0.03	16707
2025-08-18	FOLD	7.41	0.59	0.10	16273
2025-08-19	FOLD	7.33	0.59	0.00	16251
2025-08-20	FOLD	7.39	0.60	0.01	16241
2025-08-21	FOLD	7.61	0.55	0.86	17059
2025-08-22	FOLD	7.61	0.55	0.00	17156
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-28	FOLD	6.12	-71.4	-0.1	0.32
2025-07-29	FOLD	6.13	-71.4	-0.5	0.32
2025-07-30	FOLD	6.13	-71.4	-0.6	0.32
2025-07-31	FOLD	5.99	-71.4	-1.5	0.32
2025-08-01	FOLD	6.32	-71.4	1.7	0.32
2025-08-04	FOLD	6.83	17.2	23.0	0.32
2025-08-05	FOLD	6.99	17.2	20.6	0.32
2025-08-06	FOLD	6.93	22.4	44.7	0.32
2025-08-07	FOLD	6.79	22.4	44.0	0.32
2025-08-08	FOLD	6.76	22.4	45.0	0.32
2025-08-11	FOLD	6.66	22.4	44.3	0.32
2025-08-12	FOLD	6.98	22.4	48.3	0.32
2025-08-13	FOLD	7.19	22.4	47.2	0.32
2025-08-14	FOLD	7.11	22.4	44.6	0.32
2025-08-15	FOLD	7.41	22.4	47.9	0.32
2025-08-18	FOLD	7.41	22.4	45.4	0.32
2025-08-19	FOLD	7.34	22.4	44.7	0.32
2025-08-20	FOLD	7.40	22.4	45.8	0.32
2025-08-21	FOLD	7.61	22.4	47.1	0.32
2025-08-22	FOLD	7.61	22.4	45.3	0.32
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-28	FOLD	-0.00	4.19	7.31
2025-07-29	FOLD	-0.00	4.19	7.31
2025-07-30	FOLD	-0.00	4.19	7.31
2025-07-31	FOLD	-0.00	4.19	7.31
2025-08-01	FOLD	-0.00	4.19	7.31
2025-08-04	FOLD	-0.00	3.93	7.31
2025-08-05	FOLD	-0.00	3.93	7.31
2025-08-06	FOLD	-0.00	3.93	7.31
2025-08-07	FOLD	-0.00	3.93	7.31
2025-08-08	FOLD	-0.00	3.93	7.31
2025-08-11	FOLD	-0.00	3.71	7.31
2025-08-12	FOLD	-0.00	3.71	7.28
2025-08-13	FOLD	-0.00	3.71	7.28
2025-08-14	FOLD	-0.00	3.71	7.28
2025-08-15	FOLD	-0.00	3.71	7.28
2025-08-18	FOLD	-0.00	6.17	7.21
2025-08-19	FOLD	-0.00	6.17	7.21
2025-08-20	FOLD	-0.00	6.17	7.21
2025-08-21	FOLD	-0.00	6.17	7.21
2025-08-22	FOLD	0.00	6.17	7.21
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.05

Avg. EPS Est. Current Quarter

0.12

Avg. EPS Est. Next Quarter

0.17

Insider Transactions

Institutional Transactions

6.17

Beta

0.52

Average Sales Estimate Current Quarter

165

Average Sales Estimate Next Quarter

181

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-77.3

Target Price

16.09

P/E

Forward P/E

26.98

PEG

P/S

4.11

P/B

11.47

P/Free Cash Flow

EPS

-0.12

Average EPS Est. Cur. Y

0.32

EPS Next Y. (Est.)

0.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6.67

Relative Volume

0.84

Return on Equity vs Sector %

-43.3

Return on Equity vs Industry %

-30.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

45.3

Amicus Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 499

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

stock quote shares FOLD – Amicus Therapeutics, Inc. Stock Price stock today

news today FOLD – Amicus Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch FOLD – Amicus Therapeutics, Inc. yahoo finance google finance

stock history FOLD – Amicus Therapeutics, Inc. invest stock market

stock prices FOLD premarket after hours

ticker FOLD fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: FOLD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y